Cardiome Pharma Corporation (NASDAQ: CRME) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.
Insider and Institutional Ownership
55.2% of Cardiome Pharma Corporation shares are held by institutional investors. Comparatively, 59.6% of Syros Pharmaceuticals shares are held by institutional investors. 33.6% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for Cardiome Pharma Corporation and Syros Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cardiome Pharma Corporation||0||0||4||0||3.00|
Cardiome Pharma Corporation presently has a consensus target price of $7.58, indicating a potential upside of 294.97%. Syros Pharmaceuticals has a consensus target price of $26.37, indicating a potential upside of 61.37%. Given Cardiome Pharma Corporation’s higher probable upside, analysts clearly believe Cardiome Pharma Corporation is more favorable than Syros Pharmaceuticals.
Risk & Volatility
Cardiome Pharma Corporation has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of -3.79, indicating that its share price is 479% less volatile than the S&P 500.
This table compares Cardiome Pharma Corporation and Syros Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cardiome Pharma Corporation||-110.95%||-78.51%||-38.30%|
Earnings & Valuation
This table compares Cardiome Pharma Corporation and Syros Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cardiome Pharma Corporation||$23.21 million||2.80||-$17.41 million||($0.83)||-2.31|
|Syros Pharmaceuticals||$1.42 million||302.17||-$48.99 million||($2.13)||-7.67|
Cardiome Pharma Corporation has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiome Pharma Corporation, indicating that it is currently the more affordable of the two stocks.
About Cardiome Pharma Corporation
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.